617-65-2
Chemical Structure
DL-Glutamic acid
- CAS No.: 617-65-2
- Formula:C5H9NO4
- Molecular Weight:147.13
IUPAC Name: glutamic acid
InChIKey: WHUUTDBJXJRKMK-UHFFFAOYSA-N
SMILES: NC(CCC(O)=O)C(O)=O
Biological Activity: DL-Glutamic acid is a racemic amino acid mixture and an antibacterial agent. DL-Glutamic acid reduces RNA and DNA levels, with a more significant effect on RNA. DL-Glutamic acid inhibits cell division of Rhodospirillum rubrum[1].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
DL-Glutamic acid | 97.0% | DL-Glutamic acid is a racemic amino acid mixture and an antibacterial agent. DL-Glutamic acid reduces RNA and DNA levels, with a more significant effect on RNA. DL-Glutamic acid inhibits cell division of Rhodospirillum rubrum. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DL-Glutamic acid (Standard) | ≥98% | DL-Glutamic acid (Standard) is the analytical standard of DL-Glutamic acid (HY-W041895). This product is intended for research and analytical applications. DL-Glutamic acid is a racemic amino acid mixture and an antibacterial agent. DL-Glutamic acid reduces RNA and DNA levels, with a more significant effect on RNA. DL-Glutamic acid inhibits cell division of Rhodospirillum rubrum. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DL-Glutamic acid-d3 | 99.65% | DL-Glutamic acid-d3 is the d3-labeled DL-Glutamic acid (HY-W041895). DL-Glutamic acid is a racemic amino acid mixture and an antibacterial agent. DL-Glutamic acid reduces RNA and DNA levels, with a more significant effect on RNA. DL-Glutamic acid inhibits cell division of Rhodospirillum rubrum. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DL-Glutamic acid-d5 | 99.89% | DL-Glutamic acid-d5 is the deuterium labeled DL-Glutamic acid. DL-Glutamic acid is the conjugate acid of Glutamic acid, which acts as a fundamental metabolite. Comparing with the second phase of polymorphs α and β L-Glutamic acid, DL-Glutamic acid presents better stability. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
D-Glutamic acid (Standard) | 99.93% | D-Glutamic acid (Standard) is the analytical standard of D-Glutamic acid. This product is intended for research and analytical applications. D-glutamic acid, an enantiomer of L- glutamic acid, is widely used in pharmaceuticals and foods. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
D-Glutamic acid-d5 | 99.91% | D-Glutamic acid-d5 is the deuterium labeled D-Glutamic acid. D-glutamic acid, an enantiomer of L- glutamic acid, is widely used in pharmaceuticals and foods. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
D-Glutamic acid-13C5,15N | D-Glutamic acid-13C5,15N ((R)-Glutamic acid-13C5,15N) is 13C and 15N labeled D-Glutamic acid. D-glutamic acid, an enantiomer of L- glutamic acid, is widely used in pharmaceuticals and foods. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
D-Glutamic acid-13C5 | D-Glutamic acid-13C5 ((R)-Glutamic acid-13C5) is 13C labeled D-Glutamic acid. D-glutamic acid, an enantiomer of L- glutamic acid, is widely used in pharmaceuticals and foods. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Aminoadipic acid-d3 | 98.95% | Aminoadipic acid-d3 is the deuterium labeled Aminoadipic acid. Aminoadipic acid is an intermediate in the metabolism of lysine and saccharopine. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Glutamic acid (Standard) | 99.93% | L-Glutamic acid (Standard) is the analytical standard of L-Glutamic acid. This product is intended for research and analytical applications. L-Glutamic acid is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid can be used in the study of neurological diseases.
IC50 & Target:DA.
In Vitro: L-Glutamic acid (120, 500, 750, 1000 mg/dL) can reduce the harmful effect of lithium on the embryonic development of Xenopus Xenopus. L-Glutamic acid (2, 5, 10, 20 mM, 24-48 h) can induce neuroexcitotoxicity in neuroblastoma. In Vivo: L-Glutamic acid (3 g/kg, subcutaneous injection) can promote excitotoxic degeneration of retinal ganglion cells in mice. L-Glutamic acid (750 mg/kg, intraperitoneal injection) can reduce and inhibit oxidative stress induced by chlorpyrifos (CPF) in rats. |
||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Glutamic acid-13C | 99.9% | L-Glutamic acid-13C is the 13C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Glutamic acid-1-13C | 99.85% | L-Glutamic acid-1-13C is the 13C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Glutamic acid-13C2 | 99.7% | L-Glutamic acid-13C2 is the 13C labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Glutamic acid-15N | 98.0% | L-Glutamic acid-15N is the 15N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Glutamic acid-13C5,15N | 99.9% | L-Glutamic acid-13C5,15N is the 13C- and 15N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Glutamic acid-13C5,15N,d5 | 99.0% | L-Glutamic acid-13C5,15N,d5 is the deuterium, 13C-, and 15-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Glutamic acid-13C5 | 99.81% | L-Glutamic acid-13C5 is the 13C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Glutamic acid-d5 | 99.84% | L-Glutamic acid-d5 is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Glutamic acid-d3 | 99.12% | L-Glutamic acid-d3 is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Glutamine-d5 | 99.96% | L-Glutamine-d5 is the deuterium labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Glutamine-13C5,15N2,d5 | 99.95% | L-Glutamine-13C5,15N2,d5 is the deuterium, 13C-, and 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DL-Aspartic acid-d3 | 99.89% | DL-Aspartic acid-d3 is the deuterium labeled L-Aspartic acid. L-Aspartic aicd is an amino acid that can penetrate the blood-brain barrier. L-Aspartic aicd is commonly used for preparing prodrugs to target colon and cecal tissues. L-Aspartic aicd commonly used in the study of inflammatory conditions. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Aspartic acid-13C4,15N,d3 | L-Aspartic acid-13C4,15N,d3 is the 15N, deuterated, 13C-labeled L-Aspartic acid (HY-N0666). L-Aspartic acid is a NMDA receptor agonist and acidic amino acid. L-Aspartic acid has no independent analgesic activity. L-Aspartic acid can antagonize the analgesic effects of D-Aspartic acid and Morphine. L-Aspartic acid regulates polymorph transformation, crystal growth/aggregation and nucleation processes of calcium carbonate, and can serve as a biomineralization template. L-Aspartic acid promotes burst firing of central neurons. L-Aspartic acid can be used in studies related to cerebral ischemia and epilepsy. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Aspartic acid-d3 | 99.9% | L-Aspartic acid-d3 is the d3-labeled L-Aspartic acid (HY-N0666). L-Aspartic acid is a NMDA receptor agonist and acidic amino acid. L-Aspartic acid has no independent analgesic activity. L-Aspartic acid can antagonize the analgesic effects of D-Aspartic acid and Morphine. L-Aspartic acid regulates polymorph transformation, crystal growth/aggregation and nucleation processes of calcium carbonate, and can serve as a biomineralization template. L-Aspartic acid promotes burst firing of central neurons. L-Aspartic acid can be used in studies related to cerebral ischemia and epilepsy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Aspartic acid-15N,d3 | L-Aspartic acid-15N,d3 is the 15N, deuterated-labeled L-Aspartic acid (HY-N0666). L-Aspartic acid is a NMDA receptor agonist and acidic amino acid. L-Aspartic acid has no independent analgesic activity. L-Aspartic acid can antagonize the analgesic effects of D-Aspartic acid and Morphine. L-Aspartic acid regulates polymorph transformation, crystal growth/aggregation and nucleation processes of calcium carbonate, and can serve as a biomineralization template. L-Aspartic acid promotes burst firing of central neurons. L-Aspartic acid can be used in studies related to cerebral ischemia and epilepsy. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glutaric acid-d4 | 98.0% | Glutaric acid-d4 is the deuterium labeled Glutaric acid. Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Adipic acid-d44-1 | Adipic acid-d4-1 (Hexanedioic acid-d4-1) is the deuterium labeled Adipic acid (HY-W017522). Adipic acid (Hexanedioic acid) is an orally active compound with anti-HSV-1 activity. Adipic acid has low toxicity and can be used as a food additive and a gelling agent. Adipic acid can also be used in the synthesis of lubricants, artificial resins, plastics, etc. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(-)-Aspartic acid-d3 | 99.92% | (-)-Aspartic acid-d3 ((R)-Aspartic acid-d3) is the deuterium labeled (-)-Aspartic acid (HY-42068). (-)-Aspartic acid is a pyroptosis inhibitor. (-)-Aspartic acid acts as a neurotransmitter and neuromodulator, participates in hormone synthesis and regulation, and plays a role in nervous system development and endocrine system. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||